Investment Job Creation Active Pharmaceutical Ingredients Drug Development Drug Production Facilities Domestic Production Safety Standards Labor Relations Pharmaceutical Excipients Biomanufacturing Quality Assurance Tariffs Biologics Excipients Supply Chain Safety Regulations Pharmaceutical Manufacturing Safety Protocols Production Processes Production-Linked Incentive Scheme Chemical Processing Sudeep Pharma Assembly and Packaging Environmental Issues Biotechnology Drug Manufacturing Life Sciences Specialty Ingredients Global Trade Quality Control Radioligand Therapy Biopharmaceuticals Product Control International Collaboration Workplace Safety Economic Development Compliance Issues Trade Policies Cough Syrups Economic Impact U.S. Operations Corporate Leadership U.S. Manufacturing Contract Manufacturing Regulatory Affairs Factory Operations Trade Eli Lilly Production Sites Local Industry Medical Supplies RayzeBio Inc Healthcare Products Pharmaceutical Formulations Pharmaceutical Ingredients Chemical Production Production Issues Differentiated Formulations Production Facilities Investments Generics Local Production Reshoring Acquisitions
The move kick-starts Rowen’s life-sciences hub, backed by $174 million in local incentives.
